ADMA Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of 95.19% compared to ADMA Biologics's net margin of 39.44%. ADMA Biologics's return on equity of 93.41% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 35.36%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.33 which suggests that it could grow by 52.84%. Given that Catalyst Pharmaceuticals has higher upside potential than ADMA Biologics, analysts believe Catalyst Pharmaceuticals is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.605, which suggesting that the stock is 39.509% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.836, suggesting its less volatile than the S&P 500 by 16.449%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. ADMA Biologics's net income of $111.9M is higher than Catalyst Pharmaceuticals's net income of $55.9M. Notably, ADMA Biologics's price-to-earnings ratio is 22.77x while Catalyst Pharmaceuticals's PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.61x versus 5.54x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions has a net margin of 95.19% compared to ADMA Biologics's net margin of -16.54%. ADMA Biologics's return on equity of 93.41% beat Emergent BioSolutions's return on equity of -35.42%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 35.36%. On the other hand Emergent BioSolutions has an analysts' consensus of $13.50 which suggests that it could grow by 133.16%. Given that Emergent BioSolutions has higher upside potential than ADMA Biologics, analysts believe Emergent BioSolutions is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.605, which suggesting that the stock is 39.509% less volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.799, suggesting its more volatile than the S&P 500 by 79.924%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Emergent BioSolutions quarterly revenues of $189.3M. ADMA Biologics's net income of $111.9M is higher than Emergent BioSolutions's net income of -$31.3M. Notably, ADMA Biologics's price-to-earnings ratio is 22.77x while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.61x versus 0.31x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 95.19% compared to ADMA Biologics's net margin of 24.16%. ADMA Biologics's return on equity of 93.41% beat Sarepta Therapeutics's return on equity of 20.83%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 35.36%. On the other hand Sarepta Therapeutics has an analysts' consensus of $178.55 which suggests that it could grow by 76.17%. Given that Sarepta Therapeutics has higher upside potential than ADMA Biologics, analysts believe Sarepta Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.605, which suggesting that the stock is 39.509% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. ADMA Biologics's net income of $111.9M is lower than Sarepta Therapeutics's net income of $159M. Notably, ADMA Biologics's price-to-earnings ratio is 22.77x while Sarepta Therapeutics's PE ratio is 44.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.61x versus 5.94x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics has a net margin of 95.19% compared to ADMA Biologics's net margin of -540.05%. ADMA Biologics's return on equity of 93.41% beat Stoke Therapeutics's return on equity of -55.64%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 35.36%. On the other hand Stoke Therapeutics has an analysts' consensus of $23.88 which suggests that it could grow by 165.28%. Given that Stoke Therapeutics has higher upside potential than ADMA Biologics, analysts believe Stoke Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.605, which suggesting that the stock is 39.509% less volatile than S&P 500. In comparison Stoke Therapeutics has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.215%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Stoke Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are larger than Stoke Therapeutics quarterly revenues of $4.9M. ADMA Biologics's net income of $111.9M is higher than Stoke Therapeutics's net income of -$26.4M. Notably, ADMA Biologics's price-to-earnings ratio is 22.77x while Stoke Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.61x versus 27.32x for Stoke Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.